Biotech Values

[DewDiligence]

>It demonstrates that MNTA can sell its approach to big pharma.<

Two points:

1. The deal does not have an up-front signing fee per se—the initial $75M is all in the form of an equity sale.

2. MNTA now has essentially all of its future tied up with a single company (NVS). I think it would have been more bullish if MNTA had inked a major deal with a different partner.

--
MNTA’s valuation is not that cheap. Those who got out near today’s high (20.98) probably made a wise move, IMHO.